Straumann® SLActive®
Performance beyond imagination.
A new magnitude of healing power.
IMMEDIATE LOADING
High predictability in immediate loading

COMPROMISED PATIENTS
Outstanding success rates in compromised patient groups

ENHANCED BONE GRAFTING
Significantly higher formation of new bone aggregate

10 YEARS OF CLINICAL SUCCESS AND PROVEN PREDICTABILITY
For over six decades, Straumann® has made significant contributions to progress in the field of dental implants. Through pioneering innovation, we have redefined the boundaries of possibility for dental professionals and patients. We have made faster treatment, shorter healing time, and better outcomes a reality.¹ Now, the extensive healing potential of SLActive® can make this a reality for even the most challenging patients and treatment protocols.

As dental implants are now becoming a mainstream treatment option, clinicians face ever-increasing patient expectations. Patients expect successful treatment results irrespective of their bone quality, age, lifestyle, or medical history. Achieving predictable treatment outcomes has been the main focus of the SLActive® clinical development strategy. Together with leading clinicians worldwide, Straumann has studied the clinical performance of SLActive® implants under the most challenging medical conditions and treatment protocols to demonstrate the outstanding healing capacity of the SLActive® surface. As new insights emerge and new data becomes available, discover how you can benefit from the truly phenomenal performance of SLActive® to maximize your patients' healing capabilities.

**IMPLANT SURVIVAL RATE IN IMMEDIATE LOADING AFTER 10 YEARS²**
- **98.2%** survival rate
- Randomised controlled multicenter study

**IMPLANT SUCCESS RATE IN IRRADIATED PATIENTS WITH COMPROMISED BONE³**
- **100%** success rate
- Randomised clinical trial
Immediate loading with long-lasting results.

New long-term data from a randomized, controlled, multicenter study demonstrate the impressive performance of SLActive® with immediate loading. In fact, the SLActive® implants delivered a 10-year survival rate of 98.2% in this challenging protocol.²

Ever increasing patient expectations continue to drive demand for faster, safer and more efficient treatment protocols. Immediate loading allows the clinician to place a prosthetic restoration on the same day as the implant. This approach allows a patient to benefit from the restoration straightaway. However, this demanding protocol carries a higher risk of failure due to premature loading of a healing implant.
**Study设计**

**Indication**
maxilla or mandible of partially edentulous patients, with a temporary restoration (single crown or 2–4 unit fixed partial denture)

**Randomized controlled multicenter study**

<table>
<thead>
<tr>
<th>Study follow-up</th>
<th>Immediate loading</th>
<th>Early loading</th>
</tr>
</thead>
<tbody>
<tr>
<td>64 Patients</td>
<td>39 implants</td>
<td>50 implants</td>
</tr>
<tr>
<td>10 years</td>
<td>(placed the same day)</td>
<td>(placed after 28–34 days)</td>
</tr>
</tbody>
</table>

**Implant Survival Rate in Immediate Loading After 10 Years**

98.2% survival rate

**Study Conclusion**

- SLActive® implants provide a long-term highly predictable treatment option
Discover the healing power of the high-performance surface.
One of the most challenging patient groups for implant treatment includes patients who have undergone a combination of tumor surgery, chemotherapy and radiotherapy. Irradiation leads to decreased bone vascularity, impaired osteoblastic activity and reduced bone vitality, which severely compromise bone quality in these patients. The fragile mucosa and the risk of osteoradio-necrosis present further challenges. However, from a quality-of-life perspective, this patient group stands to benefit the most from implant supported prosthetic rehabilitation.

SLActive® showed a 100% success rate in irradiated patients in a recent randomized clinical trial (RCT). Based on published reviews, no other implant surface has demonstrated a 100% success rate in this patient group within an RCT setting. Remarkably, the 5-year follow-up of the trial showed that none of the surviving patients had an SLActive® implant failure. The effective implant survival rate was an outstanding 100%.

**SLACTIVE® PERFORMANCE IN IRRADIATED PATIENTS**

<table>
<thead>
<tr>
<th></th>
<th>1-year follow-up</th>
<th>5-year follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant success rate (%)</td>
<td>SLA® 96</td>
<td>SLActive® 100</td>
</tr>
<tr>
<td>Implant survival rate adjusted (%)</td>
<td>SLA® 94</td>
<td>SLActive® 100</td>
</tr>
</tbody>
</table>

Randomized Clinical Trial:
- 102 implants, 20 patients
- Post-surgery, radiotherapy and chemotherapy for oral carcinoma


** Adjusted, excluding the patients deceased due to cancer mortality.
Patients with diabetes have reduced wound healing capacity,\textsuperscript{15,16} putting dental implants at risk, particularly if the patient is unaware of the condition. Worldwide, 1 in 11 adults has diabetes, while among adults 60 years of age and older, the prevalence is twice as high.\textsuperscript{17}

Over the past 30 years, the number of people with diabetes in the US has quadrupled and, according to the US Center for Disease Control (CDC), the figure could increase to as many as one in every three adults by 2050.\textsuperscript{18} In an estimated 50\% of people with type 2 diabetes, the disease remains undiagnosed.\textsuperscript{17}
Given that half of all patients with type 2 diabetes remain undiagnosed\(^\text{17}\), how can clinicians address this risk, particularly in older patients?

**GROWING CLINICAL EVIDENCE OF HIGHLY PREDICTABLE PERFORMANCE OF SLACTIVE® IN DIABETIC PATIENTS:**

A new clinical study\(^\text{19}\) that compared SLActive® performance in patients with and without diabetes showed uncompromised performance of SLActive® implants:

- 100% implant success rate in the diabetic group
- Bone changes similar to those in healthy individuals
- Despite the observed lower levels of bone quality all implants in this study showed good primary stability

**NEW RESEARCH SHOWS THAT SLACTIVE® DEMONSTRATES HIGH ANTI-INFLAMMATORY POTENTIAL:**

- Roxolid SLActive® surface stimulates anti-inflammatory tissue response\(^\text{20}\)
- SLActive® modulates the excessive inflammatory response in diabetes, leading to improved osseointegration\(^\text{21}\)
Enhanced bone regeneration. Even at compromised sites.

Bone defects can greatly compromise the predictability of osseointegration. In a recent preclinical study\(^2\), SLActive\(^\circledR\) showed significantly higher formation of new bone aggregate within eight weeks compared to the standard Straumann\(^\circledR\) SLA\(^\circledR\) hydrophobic surface.

Buccal bone to implant contact was significantly higher in SLActive\(^\circledR\) groups as compared to standard SLA\(^\circledR\), highlighting the benefit of SLActive\(^\circledR\) to support faster bone integration, in coronal circumferential defects.

**BONE AGGREGATE FORMATION AT 8 WEEKS.**

Histological views of bone aggregate (new bone and grafting material) 8 weeks post-grafting.
• REDUCE TREATMENT TIME.¹
• REDUCE HEALING TIME.¹
• REDUCE RISK.¹

Please contact your local sales representative to get more information about the advantage of the SLActive surface now or visit slactive.straumann.com
REFERENCES


International Headquarters
Institut Straumann AG
Peter Merian-Weg 12
CH-4002 Basel, Switzerland
Phone +41 (0)61 965 11 11
Fax +41 (0)61 965 11 01
www.straumann.com

Straumann distributes both its own regenerative products and those of botiss biomaterials GmbH in selected countries under the name “Biomaterials@Straumann®”. Please contact your Straumann local partner for product availability and more information.

© Institut Straumann AG, 2016. All rights reserved.

Straumann® and/or other trademarks and logos from Straumann® mentioned herein are the trademarks or registered trademarks of Straumann Holding AG and/or its affiliates.

botiss and/or other trademarks and logos from botiss mentioned herein are the trademarks or registered trademarks of botiss dental GmbH.